Duchenne confirmatory trial fails, but Sarepta to ask FDA for full approval anyways

Sarepta Therapeutics’ long-awaited confirmatory study of two of its ‘exon-skipping’ therapies for forms of Duchenne muscular dystrophy failed to meet its primary endpoint, the company announced Monday. But despite that, the company plans to ask ...